COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evaluation of the Efficacy and Safety of Diclofenac HPBCD 75mg/ml in Treatment of Pain Following Dental Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00943098
Recruitment Status : Completed
First Posted : July 22, 2009
Results First Posted : January 28, 2013
Last Update Posted : January 28, 2013
Information provided by (Responsible Party):
IBSA Institut Biochimique SA

Brief Summary:
The present study is aimed at demonstrating the therapeutic equivalence of diclofenac HPBCD 75mg/1ml s.c. with the marketed reference product, Voltarol® 75mg/3ml i.m. in the treatment of acute moderate-to-severe pain after dental impaction surgery.

Condition or disease Intervention/treatment Phase
Dental Pain Drug: Diclofenac HPBCD s.c. 75mg/ml Drug: Voltarol 75mg/3ml i.m. Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 142 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of a Single s.c. Diclofenac HPBCD 75mg/1ml Injection as Compared to a Single i.m. Voltarol® 75mg/3ml, in the Treatment of Acute Moderate-to-severe Post-surgical Pain Following Dental Surgery (Impacted 3rd Molar Removal).
Study Start Date : September 2009
Actual Primary Completion Date : March 2010
Actual Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Diclofenac HPBCD s.c. 75mg/ml Drug: Diclofenac HPBCD s.c. 75mg/ml
1 single injection at day of dental surgical extraction

Active Comparator: Voltarol 75mg/3ml i.m. Drug: Voltarol 75mg/3ml i.m.
1 single injection at day of dental surgical extraction

Primary Outcome Measures :
  1. Pain Intensity Difference (PID) [ Time Frame: 1.5 hours ]
    Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assessed by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).

Secondary Outcome Measures :
  1. PIDs [ Time Frame: at 15 minutes post-dose. ]
  2. PIDs [ Time Frame: at 30 minutes post-dose. ]
  3. PIDs [ Time Frame: at 45 minutes post-dose. ]
  4. PIDs [ Time Frame: at 60 minutes post-dose. ]
  5. PIDs [ Time Frame: at 90 minutes post-dose. ]
  6. PIDs [ Time Frame: at 2 hours post-dose. ]
  7. PIDs [ Time Frame: at 3 hours post-dose. ]
  8. PIDs [ Time Frame: at 4 hours post-dose. ]
  9. PIDs [ Time Frame: at 5 hours post-dose. ]
  10. PIDs [ Time Frame: at 6 hours post-dose. ]
  11. PIDs [ Time Frame: at 7 hours post-dose. ]
  12. PIDs [ Time Frame: at 8 hours post-dose. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients undergoing surgical extraction of a single fully or partially impacted mandibular 3rd molar requiring bone removal.
  • Patients experiencing moderate to severe post-operative pain within 6 hours from end of surgery.
  • Pre-operative laboratory tests in the reference ranges or without clinically significant abnormalities as judged by the Investigator.

Exclusion Criteria:

  • Surgery performed under general anaesthesia, or sedation.
  • Complications occurring during the surgical procedure or in the period before randomisation as judged by the investigator.
  • Acute local or systemic infection at the time of surgery that could confound the post-surgical evaluation.
  • Patients with clinical signs of gastritis, gastro-duodenal ulcer, GI bleeding. Other GI disturbances or disease that in the opinion of the investigator could be negatively affected by the administration of NSAIDs.
  • Clinical signs or history of coagulation disorders that could be negatively affected by NSAIDs administration.
  • Hepatic or renal impairment.
  • Patients with significant cardiac impairment, history of cerebrovascular disease, history or peripheral arterial disease, uncontrolled hypertension.
  • Hypersensitivity to diclofenac or other NSAIDs or to one of the study medication components.
  • Patients under chronic treatment with topical or systemic analgesics/NSAIDs.
  • Patients under treatment with any medication that may affect the treatment efficacy evaluation.
  • Patients under treatment with any medication whose concomitant use may be susceptible to interactions with diclofenac or may affect safety.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00943098

Layout table for location information
United Kingdom
The School of Dentistry, University of Birmingham
Birmingham, United Kingdom
Department of oral Surgery; University Dental Hospital
Cardiff, United Kingdom
The School of Clinical Dentistry, The University of Sheffield
Sheffield, United Kingdom
Sponsors and Collaborators
IBSA Institut Biochimique SA
Layout table for investigator information
Principal Investigator: Ian Brook, Prof The school of Clinical Dentistry

Layout table for additonal information
Responsible Party: IBSA Institut Biochimique SA Identifier: NCT00943098    
Other Study ID Numbers: 09PUK-DCsc05
First Posted: July 22, 2009    Key Record Dates
Results First Posted: January 28, 2013
Last Update Posted: January 28, 2013
Last Verified: December 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Tooth Diseases
Stomatognathic Diseases
Facial Pain
Neurologic Manifestations
Signs and Symptoms
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action